We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's Next for Foot Locker & Why Lululemon Looks Like a Buy Before Earnings
Read MoreHide Full Article
Welcome to the latest episode of the Full-Court Finance podcast from Zacks Investment Research where Associate Stock Strategist Ben Rains breaks down Foot Locker’s (FL - Free Report) first quarter fiscal 2019 financial results that caused a huge one-day selloff. The episode then dives into why Lululemon (LULU - Free Report) stock looks like a buy heading into its anticipated Q1 earnings release later this week.
Foot Locker reported its first-quarter fiscal 2019 financial results on Friday, May 24. Shares of FL tumbled 16% at the opening bell after the company reported lower-than-projected Q1 revenues and adjusted earnings. The sneaker retailer also saw its comparable sales come in below Wall Street estimates despite solid year over year growth.
Worse yet, Foot Locker executives provided lower full-year earnings guidance. Investors should also note that companies such as Nike (NKE - Free Report) , Adidas AG (ADDYY - Free Report) , JCPenney , and many more footwear brands and retailers wrote an open letter on May 20 to President Trump urging him to reconsider his tariffs on shoes made in China. “The proposed additional tariff of 25 percent on footwear would be catastrophic for our consumers, our companies, and the American economy as a whole,” the Footwear Distributors & Retailers of America wrote.
The shoe industry as a whole has slowly moved production away from China in recent years because of rising wages and trade policies, among other reasons. China itself has also become a significant growth market for many firms, but it is worth monitoring the impact of the escalating U.S.-China trade war.
Moving on, Lululemon is currently a Zacks Rank #2 (Buy) heading into its projected first-quarter earnings release on Thursday, May 30. The yoga apparel giant has expanded in menswear, outerwear, what it calls “Office/Travel/Commute,” and much more recently in an effort to compete not only against Canada Goose GOOS, V.F. Corporation’s (VFC - Free Report) The North Face, Columbia Sportswear (COLM - Free Report) , but also the likes of the Gap (GPS - Free Report) and Macy’s (M - Free Report) .
Company management laid out in late April a five-year growth plan called the “Power Of Three.” Lululemon expects to double its men’s revenues by 2023 as it takes on Nike, Adidas, Puma, and Under Armour (UAA - Free Report) . On top of that, LULU hopes to more than double its digital revenues during this stretch. This is something Wall Street will closely watch in the Amazon (AMZN - Free Report) age that has seen giants such as Target (TGT - Free Report) roll out more compelling digital offerings in an effort to keep up. Plus, Lululemon plans to quadruple its international revenues, which includes a big push in China.
As a reminder, if you feel that we missed something, or if you have any topic suggestions, shoot us an email at podcast@zacks.com. Make sure to check out all of our other audio content at zacks.com/podcasts, and remember to subscribe and leave us a rating wherever you listen to your podcasts.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
What's Next for Foot Locker & Why Lululemon Looks Like a Buy Before Earnings
Welcome to the latest episode of the Full-Court Finance podcast from Zacks Investment Research where Associate Stock Strategist Ben Rains breaks down Foot Locker’s (FL - Free Report) first quarter fiscal 2019 financial results that caused a huge one-day selloff. The episode then dives into why Lululemon (LULU - Free Report) stock looks like a buy heading into its anticipated Q1 earnings release later this week.
Foot Locker reported its first-quarter fiscal 2019 financial results on Friday, May 24. Shares of FL tumbled 16% at the opening bell after the company reported lower-than-projected Q1 revenues and adjusted earnings. The sneaker retailer also saw its comparable sales come in below Wall Street estimates despite solid year over year growth.
Worse yet, Foot Locker executives provided lower full-year earnings guidance. Investors should also note that companies such as Nike (NKE - Free Report) , Adidas AG (ADDYY - Free Report) , JCPenney , and many more footwear brands and retailers wrote an open letter on May 20 to President Trump urging him to reconsider his tariffs on shoes made in China. “The proposed additional tariff of 25 percent on footwear would be catastrophic for our consumers, our companies, and the American economy as a whole,” the Footwear Distributors & Retailers of America wrote.
The shoe industry as a whole has slowly moved production away from China in recent years because of rising wages and trade policies, among other reasons. China itself has also become a significant growth market for many firms, but it is worth monitoring the impact of the escalating U.S.-China trade war.
Moving on, Lululemon is currently a Zacks Rank #2 (Buy) heading into its projected first-quarter earnings release on Thursday, May 30. The yoga apparel giant has expanded in menswear, outerwear, what it calls “Office/Travel/Commute,” and much more recently in an effort to compete not only against Canada Goose GOOS, V.F. Corporation’s (VFC - Free Report) The North Face, Columbia Sportswear (COLM - Free Report) , but also the likes of the Gap (GPS - Free Report) and Macy’s (M - Free Report) .
Company management laid out in late April a five-year growth plan called the “Power Of Three.” Lululemon expects to double its men’s revenues by 2023 as it takes on Nike, Adidas, Puma, and Under Armour (UAA - Free Report) . On top of that, LULU hopes to more than double its digital revenues during this stretch. This is something Wall Street will closely watch in the Amazon (AMZN - Free Report) age that has seen giants such as Target (TGT - Free Report) roll out more compelling digital offerings in an effort to keep up. Plus, Lululemon plans to quadruple its international revenues, which includes a big push in China.
As a reminder, if you feel that we missed something, or if you have any topic suggestions, shoot us an email at podcast@zacks.com. Make sure to check out all of our other audio content at zacks.com/podcasts, and remember to subscribe and leave us a rating wherever you listen to your podcasts.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>